Chou, T.-H.; Hao, Z.; Alba, D.; Lazo, A.; Gallo Afflitto, G.; Eastwood, J.D.; Porciatti, V.; Guy, J.; Yu, H. Mitochondrially Targeted Gene Therapy Rescues Visual Loss in a Mouse Model of Leber’s Hereditary Optic Neuropathy. International Journal of Molecular Sciences 2023, 24, 17068, doi:10.3390/ijms242317068.
Chou, T.-H.; Hao, Z.; Alba, D.; Lazo, A.; Gallo Afflitto, G.; Eastwood, J.D.; Porciatti, V.; Guy, J.; Yu, H. Mitochondrially Targeted Gene Therapy Rescues Visual Loss in a Mouse Model of Leber’s Hereditary Optic Neuropathy. International Journal of Molecular Sciences 2023, 24, 17068, doi:10.3390/ijms242317068.
Chou, T.-H.; Hao, Z.; Alba, D.; Lazo, A.; Gallo Afflitto, G.; Eastwood, J.D.; Porciatti, V.; Guy, J.; Yu, H. Mitochondrially Targeted Gene Therapy Rescues Visual Loss in a Mouse Model of Leber’s Hereditary Optic Neuropathy. International Journal of Molecular Sciences 2023, 24, 17068, doi:10.3390/ijms242317068.
Chou, T.-H.; Hao, Z.; Alba, D.; Lazo, A.; Gallo Afflitto, G.; Eastwood, J.D.; Porciatti, V.; Guy, J.; Yu, H. Mitochondrially Targeted Gene Therapy Rescues Visual Loss in a Mouse Model of Leber’s Hereditary Optic Neuropathy. International Journal of Molecular Sciences 2023, 24, 17068, doi:10.3390/ijms242317068.
Abstract
Leber’s hereditary optic neuropathy (LHON) is a common mitochondrial genetic disease, causing irreversible blindness in young individuals. Current treatments are inadequate, and there is no definitive cure. This study evaluates the effectiveness of delivering wildtype human NADH ubiquinone oxidoreductase subunit 4 (hND4) gene using mito-targeted AAV(MTSAAV) to rescue LHOH mice. We observed declining pattern electroretinograms amplitudes as mice aged across all groups (P< 0.001), with significant differences among groups (P = 0.023, Control vs. LHON, P = 0.008; Control vs. Rescue, P = 0.228). Inner retinal thickness and intraocular pressure do not change significantly with age or groups. Compared to LHON mice, those rescued with wildtype hND4 exhibit improved retinal visual acuity (0.29± 0.1 cy/deg vs.0.15 ± 0.1 cy/deg) and increased functional hyperemia response (effect of flicker, P<0.001, effect of Group, P=0.004; Interaction Flicker x Group, P<0.001). Postmortem analysis shows a marked reduction in retinal ganglion cell density in the LHON group compared to the other groups (Effect of Group, P<0.001, Control vs. LHON, P<0.001, Control vs. Rescue, P=0.106). These results suggest that MTSAAV-delivered wildtype hND4 gene rescues, at least in part, visual impairment in an LHON mouse model and has the therapeutic potential to treat this disease.
Keywords
LHON; MTSAAV; human ND4; gene therapy
Subject
Medicine and Pharmacology, Ophthalmology
Copyright:
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
,
,
*
